Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

EIP Pharma initiates phase II study of neflamapimod in cognitive dysfunction associated with DLB

July 15, 2019

Interim phase Ib data on ACI-24 to treat Alzheimer's disease-like symptoms in Down syndrome

July 12, 2019

Novartis and Amgen discontinue pivotal studies of CNP-520 for Alzheimer's disease

July 12, 2019

Roche discloses new gamma-secretase inhibitors

July 12, 2019

Lundbeck describes new PDE1 inhibitors

July 12, 2019

NDFIP1 may be a novel target for prevention and treatment of Parkinson's disease

July 12, 2019

New insights into old Fountain of Youth

July 11, 2019

Results presented from the international pivotal phase III PLEO-CMT study of PXT-3003

July 10, 2019

EIP Pharma initiates phase II study of neflamapimod for the treatment of cognitive deficits in HD

July 10, 2019

Disordered protein domains stay disordered at work

July 10, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...
GABA signaling linked to immune resistance in some tumors
BioWorld
Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...